Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet ...

To Read the Recap, Click Here. PODD convened 1,000 senior drug delivery executives from pharmaceutical, biotech, medical device, and across all areas of drug delivery focused on developing more ...

We recently compiled a list of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. Insulet Corporation is among the best value stocks. TheFly reported on March 13 that Truist ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Insulet Corporation is one of them. Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin ...

The PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA. “In ...

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares.

Insulet Corporation's Omnipod 5 System received FDA clearance for type 2 diabetes in August. Insulet reported a 26% year-over-year revenue increase in Q2 2024, driven by strong demand for Omnipod 5.

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 78.5% compared with 7.3% growth of the industry during the same time frame. The S&P 500 ...